Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that comp
AnaptysBio Charts Path To Split Into Two Public Companies By 2026
01:59pm, Tuesday, 30'th Sep 2025
AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.
AnaptysBio, Inc. - Special Call
09:27pm, Monday, 29'th Sep 2025
AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Dennis Mulroy - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Res
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
04:05pm, Monday, 29'th Sep 2025
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
04:05pm, Monday, 29'th Sep 2025
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced today that its
Anaptys Announces Participation in September Investor Conferences
04:15pm, Wednesday, 27'th Aug 2025
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
08:56pm, Wednesday, 06'th Aug 2025
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
06:25pm, Wednesday, 06'th Aug 2025
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.71 per share a year ago.
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
04:15pm, Wednesday, 06'th Aug 2025
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial
AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential
01:33pm, Tuesday, 10'th Jun 2025
Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement
03:39pm, Friday, 06'th Jun 2025
AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also b
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
02:23pm, Wednesday, 04'th Jun 2025
AnaptysBio, Inc. ANAB on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
04:05pm, Tuesday, 03'rd Jun 2025
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that inve
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
06:45pm, Monday, 05'th May 2025
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1.64 per share a year ago.
